Cogent Biosciences Reports Q2 2026 Financial Results

What Happened

• Cogent Biosciences, Inc. (COGT) filed a Current Report on Form 8‑K dated August 10, 2026 to announce its operating and financial results for the quarter ended June 30, 2026. The company issued a press release with those results on August 10, 2026.

Key Details

• The announcement was made under Item 2.02 (Results of Operations and Financial Condition) of Form 8‑K.
• The press release announcing the quarterly results is furnished as Exhibit 99.1 and is incorporated by reference into the 8‑K.
• The filing also includes the Inline XBRL‑formatted cover page (Exhibit 104).
• The 8‑K is limited to the press release disclosure; no other corporate actions (e.g., executive changes or mergers) are reported in this filing.

Why It Matters

• This 8‑K is the company’s official short-form disclosure that its quarterly earnings and financial condition for the period ended June 30, 2026 have been released. For investors, the attached press release is the primary source for revenue, earnings, cash position, and other metrics that can affect the stock.
• Retail investors should read the attached press release and any subsequently filed quarterly report (Form 10‑Q) for the detailed financial statements and management discussion to evaluate company performance and runway.